Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.

Authors: Hyo S. Han, Kevin Kalinsky, Nour Abuhadra, Antonio Giordano, David Starks, Gerburg M. Wulf, Nicholas Patrick McAndrew, Joyce O'Shaughnessy, Alexander I. Spira, Nancy Chan, Kristen Kelley, Ritesh Parajuli, Amy M. Weise, Arvind Chaudhry, Judy S. Wang, Debra L. Richardson, Dario R. Roque, Funda Meric-Bernstam, Caroline Rogalski, Erika P. Hamilton

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1141

Source: Full article

---

Abstract

TPS1141